The global cell and gene therapy clinical trials market size was valued at USD 12.62 billion in 2025. The market is projected to grow from USD 14.61 billion in 2026 to USD 47.16 billion by 2034, exhibiting a CAGR of 15.77% during the forecast period. North America dominated the market with a 41% revenue share in 2025.
Cell and Gene Therapy Clinical Trials Market Overview
The cell and gene therapy clinical trials market is experiencing substantial growth as pharmaceutical companies, biotechnology firms, and research organizations increasingly invest in advanced treatment development. Cell and gene therapies are innovative approaches designed to treat or potentially address the underlying causes of diseases by modifying cellular functions or introducing, replacing, or altering genetic material.
Clinical trials play a critical role in evaluating the safety, efficacy, and long-term outcomes of these therapies before regulatory approval. The increasing development of treatments for cancer, rare genetic disorders, inherited diseases, and other complex conditions is creating demand for specialized clinical research services.
Unlike conventional drug trials, cell and gene therapy studies often require advanced manufacturing processes, specialized patient monitoring, complex logistics, and long-term follow-up. These requirements are increasing the need for experienced contract research organizations (CROs) that can support clinical development from early-stage research through late-stage trials.
Key Factors Driving Market Growth
Increasing Investment in Advanced Therapies
Growing investment in biotechnology research and the development of innovative treatments is a major factor driving the cell and gene therapy clinical trials market. Pharmaceutical and biotechnology companies are expanding their clinical pipelines to investigate therapies for conditions with limited treatment options.
The development of personalized and precision medicine is also contributing to demand for specialized clinical trial services. As more candidates enter clinical development, sponsors require research partners with expertise in trial design, patient recruitment, regulatory compliance, and clinical data management.
Rising Demand for Treatments for Rare Diseases
Cell and gene therapies offer potential treatment options for certain rare and inherited diseases. These conditions may require highly specialized clinical trial designs, targeted patient recruitment, and long-term safety assessments.
The need to evaluate treatment outcomes in relatively small patient populations is encouraging sponsors to work with CROs that have experience in rare disease research and complex clinical development programs.
Growing Role of Contract Research Organizations
CROs are becoming important partners in the clinical development of cell and gene therapies. They provide services such as clinical trial management, regulatory support, site selection, patient recruitment, data management, and safety monitoring.
Outsourcing these activities can help biotechnology companies access specialized expertise and manage the operational complexity of clinical trials. The increasing number of advanced therapy programs is expected to support demand for integrated CRO services.
Advancements in Clinical Trial Technologies
Digital health technologies, advanced data analytics, and decentralized clinical trial capabilities are improving the management of complex studies. These tools can support patient monitoring, data collection, and coordination among clinical research sites.
In cell and gene therapy trials, specialized logistics and patient tracking are particularly important because some treatments involve individualized manufacturing, complex administration procedures, and extended follow-up periods.
Cell and Gene Therapy Clinical Trials Market Trends
The market is being shaped by several developments in advanced therapy research and clinical trial management.
One important trend is the growing focus on specialized CRO services for cell and gene therapies. These trials may require expertise in handling biological materials, coordinating treatment delivery, and maintaining strict quality and regulatory standards.
Another trend is the increasing use of personalized treatment approaches. Some cell therapies are developed using a patient's own cells, creating additional requirements for manufacturing coordination and chain-of-identity tracking.
The expansion of gene editing technologies and viral and non-viral delivery platforms is also broadening the range of therapies entering clinical development. As research programs become more complex, sponsors are increasingly seeking clinical research partners capable of managing specialized trial requirements.
Cell and Gene Therapy Clinical Trials Market Regional Insights
North America
North America dominated the global cell and gene therapy clinical trials market with a 41% revenue share in 2025. The region benefits from an established biotechnology ecosystem, significant investment in clinical research, advanced healthcare infrastructure, and the presence of major pharmaceutical companies and CROs.
The U.S. plays an important role in advanced therapy development due to its research institutions, biotechnology companies, clinical trial networks, and regulatory infrastructure. These factors support demand for specialized clinical trial management and development services.
Europe
Europe represents an important market for cell and gene therapy clinical trials due to its established pharmaceutical industry, research institutions, and clinical trial infrastructure. Collaboration among biotechnology companies, academic centers, and research organizations supports the development of advanced therapies.
Regulatory requirements, specialized manufacturing capabilities, and access to experienced clinical investigators also influence the region's market development.
Asia Pacific
The Asia Pacific market is expected to benefit from expanding clinical research capabilities, growing biotechnology investment, and increasing participation in global clinical development programs. Countries such as China, Japan, South Korea, and Australia are important contributors to the region's clinical research ecosystem.
The availability of clinical trial sites, growing research infrastructure, and demand for innovative treatments are creating opportunities for CROs supporting cell and gene therapy studies.
Competitive Landscape of the Cell and Gene Therapy Clinical Trials Market
The competitive landscape includes global CROs and specialized clinical research providers that support the development of advanced therapies. These companies offer services across clinical trial planning, patient recruitment, regulatory support, data management, and trial execution.
Key companies operating in the market include:
- IQVIA Inc.: Provides clinical research services, technology solutions, and analytics to support pharmaceutical and biotechnology companies throughout clinical development.
- Laboratory Corporation of America Holdings (Labcorp): Offers drug development services, including clinical trial management and laboratory capabilities that support complex clinical research programs.
- ICON plc: Provides outsourced clinical development services, including trial planning, site management, patient recruitment, and clinical data solutions.
- Charles River Laboratories: Supports drug discovery and development through research services, including capabilities relevant to the development of advanced therapeutics.
- Parexel International (MA) Corporation: Offers clinical research, regulatory consulting, and clinical development services for pharmaceutical and biotechnology companies.
- Syneos Health: Provides clinical development and related services that support the planning and execution of clinical trials.
- Medpace: Offers full-service clinical research services, including clinical operations, regulatory support, laboratory services, and data management.
- Novotech: Specializes in biotechnology-focused CRO services, supporting clinical development programs across multiple therapeutic areas and regions.
Competition among these providers is influenced by their scientific expertise, global clinical trial networks, regulatory knowledge, patient recruitment capabilities, and ability to manage complex advanced therapy studies.
Challenges in the Cell and Gene Therapy Clinical Trials Market
Despite strong growth prospects, the market faces several challenges. Cell and gene therapy trials can involve high development costs, complex manufacturing requirements, and specialized logistics. Maintaining the quality and consistency of biological materials is particularly important throughout the clinical development process.
Patient recruitment can also be difficult for rare diseases because eligible patient populations may be small and geographically dispersed. In addition, some therapies require long-term follow-up to evaluate durability of response and potential delayed adverse effects.
Regulatory complexity and evolving requirements across countries can further increase trial timelines and operational costs. Addressing these challenges will require collaboration among sponsors, CROs, research institutions, regulators, and specialized manufacturing providers.
Get Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cell-and-gene-therapy-clinical-trial-market-110790
Future Outlook
The global cell and gene therapy clinical trials market is projected to grow from USD 12.62 billion in 2025 to USD 47.16 billion by 2034, reflecting a CAGR of 15.77% during the forecast period.
The expansion of advanced therapy pipelines, increasing biotechnology investment, and rising demand for specialized clinical research services are expected to support market growth. CROs with expertise in complex trial management, patient recruitment, regulatory strategy, and advanced therapy logistics may benefit from these developments.
As cell and gene therapies progress through clinical development, continued innovation and collaboration across the biotechnology and pharmaceutical industries are expected to shape the market's long-term outlook.
Explore Japan’s Market Opportunities - Latest- Cell And Gene Therapy Clinical Trial Market- Insights
Comments